NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
NEXGEL Appoints Ian Blackman as Chief Financial Officer
NexGel Calls Celularity Wound Deal “Transformational,” Eyes $35M Revenue and EBITDA Profitability
NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
Financial Comparison: NexGel (NASDAQ:NXGL) and Pressure BioSciences (OTCMKTS:PBIO)
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
NexGel (NXGL) Expected to Announce Earnings on Monday
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
Head to Head Survey: Pacific Biosciences of California (NASDAQ:PACB) and NexGel (NASDAQ:NXGL)
NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence
Contrasting NexGel (NASDAQ:NXGL) and Teleflex (NYSE:TFX)
NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
NEXGEL, Inc. (NXGL) Q3 2025 Earnings Call Transcript
NEXGEL Reports Third Quarter 2025 Financial Results
Wall Street Week Ahead
NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript
NEXGEL to Report Second Quarter 2025 Financial Results on August 12th
NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors
NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement
NEXGEL and STADA AG Announce Expansion of Partnership for North America
NEXGEL, Inc. (NXGL) Q1 2025 Earnings Call Transcript
NEXGEL to Report First Quarter 2025 Financial Results on May 13th
NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript
NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results
NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th
NEXGEL to Participate in Webull Consumer Virtual Webinar on February 18, 2025
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
NEXGEL, Inc. (NXGL) Q3 2024 Earnings Call Transcript
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
NEXGEL Announces $2,000,000 Registered Direct Offering
NEXGEL to Participate in Upcoming October Investor Conferences
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal
NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively